After the treatments, the BFXJY treatment could decrease the expression levels of NLRP3, ASC, and pro-Caspase-1 compared to that in Qi-yin deficiency + LPS-ATP group. The gene discussed is NLRP3; the disease is hyperinsulinemic hypoglycemia, familial, 4.